Suntinorexton

Suntinorexton (INNTooltip International Nonproprietary Name; developmental code name TAK-861) is an experimental orexin receptor agonist.^[1][2] It acts as a selective agonist of the orexin OX₂ receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.^[3] Suntinorexton superseded firazorexton (TAK-994) as a clinical drug candidate following evidence of hepatoxicity in humans.^[1] The drug has reached phase 3 clinical trials as of 2024.^[1][4] It is orally active and centrally penetrant.^[1]

Suntinorexton

Clinical data
Routes of administration	By mouth[1]
Identifiers
IUPAC name N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
CAS Number	2274802-89-8 Y
PubChem CID	137460941
UNII	FF2NQ35DA4
Chemical and physical data
Formula	C23H28F2N2O4S
Molar mass	466.54 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O
InChI InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1 Key:MQDUVMBBJZLFHF-PMACEKPBSA-N

See also

• Orexin receptor § Agonists
• List of investigational sleep drugs § Orexin receptor agonists

References

1. Konofal, Eric (2024). "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacology Biochemistry and Behavior. 241: 173804. doi:10.1016/j.pbb.2024.173804.
2. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020. Proposed INN: List 123
3. WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company.
4. "TAK 861". AdisInsight. 12 July 2024. Retrieved 30 July 2024.